Breaking News
3946 - 3960 of 6634 results
Prev
262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443
Next
August 6, 2009
Formatech has introduced a “Fillanthropy” Program, under which the company will donate an aseptic fill and finish manufacturing service each month for selected therapeutic candidates entering human trials.
Read More »
August 6, 2009
Baxter International has completed production of its first commercial batches of Celvapan A/H1N1 pandemic vaccine and is discussing distribution plans with national health authorities, subject to obtaining authorizations.
Read More »
August 6, 2009
Galapagos NV has successfully completed a Phase I trial of its drug candidate GLPG0259 for rheumatoid arthritis (RA).
Read More »
August 5, 2009
Early-stage revenues dropped 15% to $7.3 million in 2Q09, but rose 15% for YTD09
Read More »
August 5, 2009
Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand.
Read More »
August 5, 2009
DSM Pharmaceutical Products’ Greenville, NC facility has received Potent Compound Safety Certification from SafeBridge Consultants, Inc.
Read More »
August 5, 2009
AMRI's total contract services revenue dropped 16% to $38.8 million in 2Q09
Read More »
August 4, 2009
Amgen announced positive top-line results from a head-to-head trial evaluating denosumab vs. Zometa
Read More »
August 4, 2009
Gregg H. Alton has been named executive vice president, Corporate and Medical Affairs at Gilead Sciences
Read More »
August 4, 2009
Diana Hausman, M.D., has been named vice president, Clinical Development at Oncothyreon.
Read More »
August 4, 2009
The FDA has approved Livalo, a statin developed by Kowa Research Institute and Kowa Pharmaceuticals America
Read More »
August 3, 2009
Margie McGlynn, president of Merck Vaccines and Infectious Diseases, has resigned effective November 1st.
Read More »
August 3, 2009
Bristol-Myers Squibb and AstraZeneca received FDA approval for Onglyza as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Read More »
August 3, 2009
Genentech has received approval from the FDA for Avastin plus interferon-alfa for metastatic renal cell carcinoma, the most common type of kidney cancer.
Read More »
August 3, 2009
The FDA has issued a Complete Response letter to Savient Pharmaceuticals for its gout treatment Krystexxa
Read More »
3946 - 3960 of 6634 results
Prev
262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443
Next
